Headquartered in Cleveland, OH Fiscal year ends December NASDAQ: ABEO abeonatherapeutics.com
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company building a portfolio of therapies for rare and serious diseases. Its marketed product is ZEVASKYN (prademagene zamikeracel), an autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). ZEVASKYN is administered through a U.S. network of qualified treatment centers, which numbered eight as of the third quarter of 2026, and supported by the Abeona Assist patient services program. The product received CMS New Technology Add-On Payment status effective October 1, 2026. The pipeline includes ABO-801 (formerly APT-1011), a Phase 3-ready once-daily orally disintegrating tablet of fluticasone propionate for eosinophilic esophagitis, acquired from Ellodi Pharmaceuticals in November 2026. It also includes ABO-701 (PSMA-SIR-T), an investigational engineered T-cell therapy targeting PSMA. Abeona also holds rights to commercial milestones and tiered royalties of up to 8% on Ultragenyx's FAYUVI, a gene therapy for Sanfilippo Syndrome Type A that Abeona advanced before licensing it out in 2022. Updated
The narrower loss leans on a $6.5 million non-cash warrant gain, while revenue came in missing expectations after one treatment batch failed an identity assay and could not be booked. The ZEVASKYN ramp is the line to track: six treatments completed in the quarter, 15 since launch, with Medicare NTAP reimbursement live as of October 1.
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company building a portfolio of therapies for rare and serious diseases.
The Wall Street consensus 12-month price target for ABEO is $18.38.